Last reviewed · How we verify

ALGLUCOSIDASE ALFA (MYOZYME) — Competitive Intelligence Brief

ALGLUCOSIDASE ALFA (MYOZYME) (ALGLUCOSIDASE ALFA (MYOZYME)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic disease / Metabolic disorder.

marketed Enzyme replacement therapy Acid alpha-glucosidase (GAA) Rare genetic disease / Metabolic disorder Small molecule Live · refreshed every 30 min

Target snapshot

ALGLUCOSIDASE ALFA (MYOZYME) (ALGLUCOSIDASE ALFA (MYOZYME)) — Genzyme, a Sanofi Company. Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme that breaks down glycogen accumulated in lysosomes, restoring normal cellular function in Pompe disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ALGLUCOSIDASE ALFA (MYOZYME) TARGET ALGLUCOSIDASE ALFA (MYOZYME) Genzyme, a Sanofi Company marketed Enzyme replacement therapy Acid alpha-glucosidase (GAA)
creon 35.000 Ph.U (R) creon 35.000 Ph.U (R) Hospital Clinico Universitario de Santiago marketed Pancreatic enzyme replacement therapy
Panzytrat 25.000 FIP-E units of Lipase Panzytrat 25.000 FIP-E units of Lipase Foundation for Liver Research marketed Pancreatic enzyme replacement therapy Triglycerides and dietary lipids
RDD to Palynziq RDD to Palynziq BioMarin Pharmaceutical marketed Enzyme replacement therapy Phenylalanine ammonia-lyase (PAL)
Pancrelipase Capsules Pancrelipase Capsules Ohio State University marketed Pancreatic enzyme replacement therapy
Cerezyme® Cerezyme® ISU Abxis Co., Ltd. marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase)
Myozyme® (alglucosidase alfa) Myozyme® (alglucosidase alfa) Genzyme, a Sanofi Company marketed Enzyme replacement therapy Acid alpha-glucosidase (GAA); lysosomal glycogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALGLUCOSIDASE ALFA (MYOZYME) — Competitive Intelligence Brief. https://druglandscape.com/ci/alglucosidase-alfa-myozyme. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: